TCGA-21-1077-01A-01R-0692-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- MYC_TARGETS_V1+0.490
- MTORC1_SIGNALING+0.430
- OXIDATIVE_PHOSPHORYLATION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- HEDGEHOG_SIGNALING+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- HYPOXIA+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.240
- ANGIOGENESIS-0.140
- PANCREAS_BETA_CELLS-0.140
- COAGULATION-0.100
- COMPLEMENT-0.100
- KRAS_SIGNALING_DN-0.100
- KRAS_SIGNALING_UP-0.100
- TGF_BETA_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-5473-01A-01R-1635-07 | — | cohortSQ2 | 0.886 |
| 2 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.872 |
| 3 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.847 |
| 4 | TCGA-52-7810-01A-11R-2125-07 | — | cohortSQ1 | 0.846 |
| 5 | TCGA-92-7341-01A-31R-2045-07 | — | cohortSQ2 | 0.844 |
| 6 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.840 |
| 7 | 56218_S133 | — | cohortSQ1 | 0.840 |
| 8 | TCGA-66-2800-01A-01R-1201-07 | — | cohortSQ2 | 0.838 |
| 9 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.833 |
| 10 | MDT-AP-0322 | Med | Medulloblastoma | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |